© 2023 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
In a recent study, patients with lung cancer who used an online app to track their symptoms saw a higher overall survival rate than those who didn't.
Patients with lung cancer who participated in a web-based system for reporting and tracking their symptoms achieved dramatic gains in survival compared with individuals who were followed with typical protocols, according to study results presented during the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of over 30,000 oncology professionals in Chicago.
The MoovCare system made a difference for patients because it resulted in early detection of dangerous conditions or recurrences, resulting in healthier individuals who were better able to undergo optimal therapy and earlier supportive care that improved quality of life, said lead study author Fabrice Denis, during an ASCO presscast.
The median overall survival (OS) rate for patients who used the MoovCare system was 19 months compared with 12 months for participants in the control group, after 20 months of follow-up. Additionally, 75 percent of the patients followed through MoovCare were still alive at one year versus 49 percent with standard procedures.
There also was a 50 percent reduction in the average number of imaging tests per patient per year with the use of the app, said Denis, a researcher at the Institut Inter-regional de Cancérologie Jean Bernard in Le Mans, France. These improvements were achieved even though the relapse rates were similar for both groups—49 percent among those who used the app and 51 percent among those with typical follow-up, researchers reported.
However, performance scores stayed higher among patients who used MoovCare. As a result, 74 percent of these patients were able to undergo optimal therapy upon relapse compared with 33 percent who had not used the app.
Denis said the need for an app in lung cancer is particularly pressing. “There are no standard follow-ups to detect relapse in patients,” he said. “Relapses are frequent and often symptomatic… Symptomatic patients often wait, leading to health degradation and nonoptimal therapy.”
MoovCare consists of a software application that patients or their caregiver use to report their symptoms. The algorithm analyzes the information for signals of potential relapse or complications and, if necessary, notifies the oncology care provider via email. The app can be accessed on mobile and desktop devices.
Denis and colleagues tested the system in a phase 3 trial conducted at five medical centers in France. Results were reported for 121 patients in the intent-to-treat analysis who were randomized to use either the MoovCare system or routine follow-up. The trial was stopped early at the interim analysis because of the positive results.
The study population consisted of patients with nonprogressive non—small cell lung cancer or small cell lung cancer at stages 2A through 4. All patients underwent chemotherapy before starting the trial and were permitted to continue tyrosine kinase inhibitor therapy or maintenance therapy throughout the study.
In response to questions about MoovCare’s practicality, Denis said the system is easy to install on a computer and would simply require a doctor or nurse to monitor the emails.
However, Patricia Ganz, an ASCO commentator who served as moderator for the presscast, said drawing benefit from such a system would necessitate changes in US practices. She said that similar experiments in the United States had found that information patients submit electronically does not generate action because of the cost of deploying personnel to monitor the data.
“We’re trying to restructure how we deliver care so that we can be responsive to these kinds of changes and these tools where patients can report their symptoms and how they’re doing on a regular basis,” said Ganz, a professor at the UCLA Fielding School of Public Health/Department of Health Policy and Management. “If there’s staff in the office who can respond [it would] really make a difference in preventing emergency room visits, hospitalizations and so forth.”
ASCO spokesman Gregory Masters, a lung cancer specialist at the Helen F. Graham Cancer Center in Delaware, said the MoovCare system presents “one way to engage patients and allow them to take a more active role in their care.”
He said this is particularly important in lung cancer. “Lung cancer is a unique cancer in some ways because many of these patients have a lot of guilt about their diagnosis,” said Masters. “I think we see that more in lung cancer patients than in many other patients. Some patients don’t want to bother the doctor or the nurse or the health care team with their symptoms or they think [their symptoms] are not important.”
Sivan Innovation, an e-health company headquartered in Jerusalem that developed MoovCare, said the system is the first web application based on telemonitoring. The company said it would seek regulatory approvals for marketing it as a medical device and that a CE mark procedure is underway in Europe.
The company also said it would start rolling out the application in France in 2017, and then elsewhere in Europe, the United States, Israel and other countries. MoovCare also is in development for approximately 15 other cancer indications, notably lymphoma, in a partnership with Takeda France, the company said.